The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwaitkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WT, Robertson AG, Spellman PT, Rathmell WK, Linehan WM (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 23

Pages Range: 313-326.e5

Journal Issue: 1

DOI: 10.1016/j.celrep.2018.03.075

Abstract

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival.

Involved external institutions

National Cancer Institute (NCI) United States (USA) (US) Vanderbilt University United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Centura Health United States (USA) (US) Memorial Sloan Kettering Cancer Center United States (USA) (US) Van Andel Institute United States (USA) (US) University of North Carolina at Chapel Hill United States (USA) (US) British Columbia Cancer Agency Canada (CA) Eli and Edythe L. Broad Institute of MIT and Harvard United States (USA) (US) Dana–Farber Cancer Institute United States (USA) (US) Houston Texas Medical Center United States (USA) (US) University of Kansas (KU) United States (USA) (US) Brigham and Women's Hospital (BWH) United States (USA) (US) Washington University in St. Louis United States (USA) (US) Mayo Clinic in Arizona United States (USA) (US) Harvard University United States (USA) (US) Oregon Health and Science University (OSHU) United States (USA) (US) Leukemia Therapeutics LLC United States (USA) (US) Yale University United States (USA) (US)

How to cite

APA:

Ricketts, C.J., De Cubas, A.A., Fan, H., Smith, C.C., Lang, M., Reznik, E.,... Linehan, W.M. (2018). The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 23(1), 313-326.e5. https://doi.org/10.1016/j.celrep.2018.03.075

MLA:

Ricketts, Christopher J., et al. "The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma." Cell Reports 23.1 (2018): 313-326.e5.

BibTeX: Download